


ProvLab HIV Diagnostic Algorithm:



New to the HIV Diagnostic Algorithm:

- Western blot confirmation will be replaced by the Geenius™ HIV-1/2 Antibody Differentiation Assay
- All indeterminate and negative Antibody Differentiation tests will be confirmed with **HIVQUAL**
 - ***A new EDTA sample is required for HIVQUAL assay***
- HIVQUAL has been validated by ProvLab for use in diagnostics of HIV, and will give a positive, negative or indeterminate result.
- Follow up EDTA samples for HIVQUAL:
 - ProvLab has implemented an active reminder to physicians that will be triggered when samples for HIVQUAL exceed 10 days.

Testing Guidelines:

- All first and second time positive samples will be confirmed by Antibody Differentiation
- Samples testing positive ≥ 3 times will not be reconfirmed
 - These patients should be monitored via HIV viral load testing

Special Populations:**1. Infants Born to HIV Positive Mothers:**

- a. Proviral DNA and HIVQUAL should be used for detection of active infection
- b. Antibody detection will represent maternal antibodies, and therefore serology cannot be used for HIV diagnosis in infants <18 months of age

2. Investigation of Elite Suppressor Status:

- a. Patients who are repeatedly reactive by serology, but have never had a positive result by a molecular assay, and who are not on treatment, should be investigated as a possible elite suppressor.
- b. If the initial viral load is found to be <40 copies/ml, the viral load should be repeated before initiating any treatment, and a second viral load should be obtained within approximately 3 months of the first.
 - i. If both viral loads are undetectable, this should trigger communication with a laboratory virologist to review the serologic results and initiate further laboratory testing, which would likely include Proviral DNA.
- c. The laboratory itself cannot reliably identify these patients, as treatment information is either unavailable, or incomplete. Therefore, the physician should trigger consultation with the laboratory for further follow-up of these patients.